Sun Pharma signs pact with CMS for generic drug sales in China
Category: #health  By Pankaj Singh  Date: 2019-08-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sun Pharma signs pact with CMS for generic drug sales in China
  • The pharmaceutical company has entered into an agreement with China Medical System Holdings to manufacture and manage 7 generic products in Mainland China.
     
  • The company shares rose to 4.69% to hit a day high of Rs. 434.20 on the BSE.

Mumbai based Sun Pharma has reportedly inked a licensed collaboration with China Medical System Holdings for the sales of seven generic pharmaceutical products in Mainland China. Apparently, the Sun Pharma share price elevated as much as 4.7% to hit high of Rs. 434.20 compared with its closing price of Rs.414.70 on Friday on the National Stock Exchange.

As per trusted reports, one of the subsidiaries of the company initiated an agreement with CMS Holdings to manufacture and promote and manage 7 generic products in Mainland China.

For the uninitiated, Hong Kong based China Medical System Holdings is an investment holding company primarily engaged in the manufacturing, advertising and promotion of the pharmaceutical products.

As per sources with the knowledge on the matter, the company’s collaboration with CMS would now comprise over 8 generic products. The overall addressable market size for the products has been estimated to be about USD 1 billion in Mainland China. The preliminary terms of the agreement have been kept for 20 years from the first commercial sale of the products in Mainland China and are expected to be extended for additional 3 years' according to the mutually agreed contract between the two parties.

Speaking on the collaboration, Dilip Shanghvi, the managing director at Sun Pharma cited that the collaboration offers the company an entry into the Chinese pharmaceutical market. With over more than 65% penetration of generics in the nation, China characterizes a significant opportunity for generic pharmaceutical companies, Shanghvi added.

Apparently, the Sun Pharma shares closed 2.66% higher at Rs. 425.80 outdoing the Sensex which rose over 0.14%.

Post the announcement, the shares of Sun Pharma rose to 4.69% up to Rs. 434.20 on BSE.

Source credit: https://www.ndtv.com/business/sun-pharma-share-price-sun-pharma-surges-on-agreement-to-sell-generic-products-in-mainland-china-2087037

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
By Pankaj Singh

The manuscript includes data of the first four trial participants that were treated with RP-L102 under the Phase 1/2 FANCOLEN-I study.   First RP-L102 trail data demonstrates increase in bone marrow engraftment levels, which further leads to...

Shopify buys 6 River Systems for $450M to grow its fulfillment network
Shopify buys 6 River Systems for $450M to grow its fulfillment network
By Pankaj Singh

Acquisition of 6 River Systems seems to be an attempt to accelerate the growth in delivery of daily packages. The deal would further expand the reach of the Shopify Fulfillment Network, which utilizes machine learning to ensure lower shipping cost...

Genentech to present new data from neuroscience portfolio at ECTRIMS
Genentech to present new data from neuroscience portfolio at ECTRIMS
By Pankaj Singh

The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.   The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neur...